Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn about a recent article by Sudeep Shivakumar et al, published in NEJM, adding:
”Congratulations to Dr. Sudeep Shivakumar and the entire EPCAT III investigative team on this outstanding achievement!
Exciting news from the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, where the EPCAT III trial was presented as a Late-Breaking Abstract with simultaneous publication in the NEJM Group.
This landmark Canadian-led RCT demonstrated that aspirin alone, initiated immediately after total hip or total knee arthroplasty, was noninferior to an initial 5-day course of rivaroxaban followed by aspirin for the prevention of symptomatic VTE, without a clinically meaningful difference in bleeding.
These are truly practice-changing results that have the potential to simplify postoperative thromboprophylaxis for millions of patients undergoing hip and knee arthroplasty worldwide while maintaining excellent efficacy and safety.”
Title: Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
Authors: Sudeep Shivakumar, Davide Matino, David Zukor, Susan R. Kahn, George Vincent, Raman Mundi, Pascal-Andre Vendittoli, Mohammad Refaei, Eric Bohm, Michael Tanzer, Stéphane Pelet, Glen Richardson, James Powell, Rick Ikesaka, James Douketis, Sarah Ward, Paul Kim, Stephen Mann, Susan Pleasance, Jocelyn Cormier, Pantelis Andreou, Kara Matheson, Chris Theriault, Carol West, David Anderson, Peter L. Gross
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 11:05Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure
-
Aug 13, 2026, 08:11Cristiana Coneru: How the Gut Microbiome Influences Venous Thrombosis